Other Press Releases

MHRA launch public health campaign
Tue, 05 Feb 2013

The MHRA is today (1st February 2013) launching a public health campaign in partnership with pharmacy organisations to highlight the need for the public to report any suspected side effects from medicines through the Yellow Card Scheme.    
The Medicines and Healthcare products Regulatory Agency (MHRA) on 1st February 2013 launched a public health campaign in partnership with pharmacy organisations to highlight the need for the public to report any suspected side effects from medicines through the Yellow Card Scheme.

The Yellow Card Scheme – was introduced in 1964... Read More

Psoriasis is more than skin deep, says NICE
Wed, 24 Oct 2012

GPs should proactively assess the impact that psoriasis may be having on the daily lives of their patients, advises the National Institute for Health and Clinical Excellence (NICE) in new guidance out today (Wednesday 24 October).

Psoriasis is a skin condition characterised by red, flaky, crusty patches of skin covered with silvery scales. It is believed to affect up to 2.2% of the UK population (i.e. over 1.3 million people) with most cases seen in young people and adults under the age of 35. The disease can contribute to low self-esteem, anxiety, embarrassment and depression,... Read More

Wales research centre to help ‘stop arthritis in its tracks'
Mon, 11 Jun 2012

Wales’ first research centre dedicated to developing new drugs and treatments to ease the pain and suffering of people with arthritis has been unveiled.

The Arthritis Research UK Experimental Arthritis Treatment Centre (CREATE), based in Cardiff University’s School of Medicine, will work alongside volunteer patients from Cardiff and the Vale University Health Board, to test drugs used in other conditions to help treat around 50 South Wales patients with rheumatoid and psoriatic arthritis.

With start-up funding of £112,500 from medical research charity Arthritis Research UK... Read More

NICE seeks views on draft psoriasis guideline
Fri, 11 May 2012

People with psoriasis should be treated by their GPs whenever possible and only referred to dermatology specialists when there is a clinical need, suggests draft guidance from the National Institute for Health and Clinical Excellence (NICE) out today (Friday 11 May).
 
In its draft guideline, NICE proposes to advise that GPs and other non-specialist healthcare professionals should only refer patients to dermatology specialists if they are uncertain about the diagnosis, the psoriasis is severe or extensive, the condition can't be controlled with topical therapies (such as... Read More

Improving patient choice
Thu, 12 Apr 2012

Patients in parts of London, Manchester and Salford and Nottingham will shortly be able to register with a GP practice of their choice for the first time.

Under Government plans to allow patients to choose the GP surgery that best suits their needs, from April they will be free to register with any practice in their city, for example near their workplace or home.

It means people in these major cities, like commuters who are often away from their local area during the working day, will find it easier to see their doctor where it suits them.

The pilot scheme will run... Read More

Is there something you hate about your body that you would do anything to change?
Thu, 29 Mar 2012

Maverick TV, the Producers of Channel 4’s Embarrassing Bodies have started production on the second series of My Naked Secret for a major International Broadcaster. 

We are looking for members of the public suffering in silence because of something they hate about their bodies.  From birthmarks to  scarring, breast problems, male breasts, vein problems, excess skin, hair problems, damage post surgery or other conditions where the physical symptoms have caused the sufferer to hide away under layers of clothing or make up.  You name it, we want to help.

My... Read More

MHRA updates advice for metal-on-metal hip replacements
Tue, 28 Feb 2012

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued updated advice to surgeons that patients with a particular type of metal-on-metal hip replacement should be monitored annually for the life of the hip replacement. This updates previous advice from April 2010 that patients with this type of hip replacement need only be monitored for a minimum of five years after their operation.

The updated advice is included in a new MHRA Medical Device Alert that has been issued to clinicians  for the management of patients with these... Read More

Biologics register for people with psoriasis
Wed, 22 Feb 2012

Help for psoriasis sufferers: a web-based register of biologic and conventional therapies for psoriasis established by the BAD in the UK

A study on The British Association of Dermatologists’ Biologic Interventions Register (BADBIR): a web-based register of biologic and conventional systemic therapies for psoriasis has been published in the British Journal of Dermatology.

Psoriasis is a common, skin condition affecting approximately 2% of the UK population.  Many patients find that conventional topical and... Read More

New SIGN guideline is “missing link” for improved care.
Fri, 05 Nov 2010

Guideline calls for more joined-up care between dermatologists and rheumatologists.

The authors of a groundbreaking guideline on psoriasis and psoriatic arthritis recently published believe that it is the “missing link” that will bring about improved diagnosis and treatment by GPs in primary care.

The guideline also emphasises that greater co-ordination in the care delivered by dermatologists and rheumatologists can result in much improved outcomes for patients.

The guideline from the Scottish Intercollegiate Guidelines Network (SIGN), part of NHS Quality Improvement... Read More

NICE final guidance recommends improved access to psoriatic arthritis drugs
Thu, 26 Aug 2010

Three treatments for psoriatic arthritis are recommended in final guidance (TA 199) published by the National Institute of Health and Clinical Excellence
(NICE) on 25 August 2010.

Etanercept, infliximab and adalimumab are all recommended for the treatment of active and progressive psoriatic arthritis, based on specific criteria:

  • The person has peripheral arthritis with three or more tender joints and three or more swollen joints and
  • the psoriatic arthritis has not responded to adequate trials of at least two standard disease-modifying antirheumatic... Read More

Pages